MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties

Glioblastoma multiforme (GBM), also called WHO Grade IV malignant glioma, is one of the most aggressive brain cancers due to its resistance to all current forms of treatment, including drug intervention and ionizing radiation (IR). GBM can arise from primary glioblastoma or progress from a low-grade glioma. In the clinic, GBM patients have a median survival of less than 15  months [1], and GBM tumors are highly recurrent even after surgical resection, chemotherapy, radiotherapy (RT), and immunotherapy.

Source: Radiotherapy and Oncology - October 12, 2018 Category: Radiology Authors: Jang-Chun Lin, Jo-Ting Tsai, Tsu-Yi Chao, Hsin-I Ma, Chian-Shiu Chien, Wei-Hsiu Liu Tags: Original article Source Type: research